

UCSF

UC San Francisco Previously Published Works

Title

Putting women in the centre of the global HIV response is key to achieving epidemic control!

Permalink

<https://escholarship.org/uc/item/3b80k48s>

Journal

Journal of the International AIDS Society, 23(3)

ISSN

1758-2652

Authors

Karim, Quarraisha Abdool

Havlir, Diane

Phanuphak, Nittaya

Publication Date

2020-03-01

DOI

10.1002/jia2.25473

Peer reviewed

VIEWPOINT

Putting women in the centre of the global HIV response is key to achieving epidemic control!

Quarraisha Abdool Karim^{1,2,§*}, Diane Havlir^{3*}  and Nittaya Phanuphak^{4*} 

[§]**Corresponding author:** Quarraisha A Karim, CAPRISA, Nelson R Mandela School of Medicine, 771 Umbilo Road, Congella, Durban 4001, South Africa. Tel: +27-31-2604550. (quarraisha.abdoolkarim@caprisa.org)

*These authors have contributed equally to the work.

Keywords: women; HIV; prevention; treatment; transgender women; ageing

Received 13 February 2020; Accepted 14 February 2020

Copyright © 2020 The Authors. *Journal of the International AIDS Society* published by John Wiley & Sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

As we celebrate International Women's Day and the many successes that women have, and continue to achieve globally, we are also reminded of the many challenges that remain. HIV/AIDS continues to be one such challenge. In 2018, there were about 37 million people living with HIV, 900,000 AIDS-related deaths and 1.4 million new HIV infections – a sharp reminder that HIV remains a major pandemic and that we have miles to go in sustaining our current treatment successes, strengthen our prevention efforts, and address continued human rights violations and research gaps before we can claim victory against HIV.

Globally, the distribution of HIV is uneven within and between regions. Vulnerable populations across the globe are also not homogeneous. Similarly, the vulnerability of women within and between countries and regions, by sexual orientation and across their life-course differs. A nuanced and granular understanding is critical for the development of effective responses to reduce their vulnerability. A glimpse of this can be gleaned, for example, if we focus on adolescent girls and young women (AGYW; aged 15 to 24 years) – who in 2017 represented just 10% of the global population, yet accounted for 25% of all new HIV infections [1] – or transgender women who continue to face major barriers to access prevention and treatment services, or the millions of women who have benefited from access to life-saving antiretroviral treatment yet now face new challenges as they age. These issues are by no means exhaustive of the hardships facing women at risk of acquiring HIV or living with HIV, but we use the opportunity of this viewpoint to focus on these topics to share the prospects of and challenges to altering current global HIV trajectories for women and societies disproportionately impacted by HIV and to highlight the complexity and diversity of the issues facing women across their lifespan.

Sub-Saharan Africa bears a disproportionate 70% of the global burden of HIV that is spread predominantly through sex with a concomitant epidemic in infants born to mothers living

with HIV. A unique characteristic of this generalized epidemic is the high rate of HIV in AGYW, who are up to six times more likely to have HIV compared to their male peers. This early acquisition of HIV in young women is often from men who are five or more years older than them, and is central to the continued spread of HIV in this region. Four out of five of all infections occurring among adolescents in sub-Saharan Africa are in girls aged 15 to 19 years. In South Africa, home to one in five of the world's people living with HIV, 1500 AGYW acquire HIV every week [1]. Overall, AGYW are twice as likely to be living with HIV and experience higher rates of morbidity and mortality compared to their male peers.

Behavioural and biological factors such as age-disparate sexual coupling between young women and older men [2], genital inflammation [3,4] and vaginal dysbiosis [5] contribute to a young woman's vulnerability for acquiring HIV. These factors are difficult to mitigate against the backdrop of structural challenges of poverty [6], social incohesion due to migration and conflict, gender-based violence [7] and gender-power dynamics, including a woman's limited ability to negotiate safer sex with prevention technologies that depend on male cooperation. When AGYW become pregnant, they are more likely to drop out of school. This limits their employment opportunities, leading to vicious cycles of dependency on older men, and increases their risk of having a repeat pregnancy within a year and of acquiring HIV if not already living with HIV [8]. Preventing new infections in this group is therefore a high priority to alter the current epidemic trajectory in sub-Saharan Africa and get it on the path of epidemic control. The PEPFAR-funded DREAMS Project is an excellent example of an intervention targeting behavioural, biological and structural drivers of AGYW vulnerability, underscoring the importance of AGYW completing schooling, avoiding unplanned pregnancies and graduating from high school HIV-free [9]. These investments will strengthen social cohesion and realize the continent's full potential of youth as its demographic dividend.

Transgender women are among the most marginalized in society due to the general lack of legal gender recognition and criminalization of their gender identity. Stigma, discrimination and unavailability of transgender-competent healthcare are key barriers for transgender women to address their basic health needs [10]. In Thailand, for example, 48% of transgender women have never seen a doctor regarding the use of feminizing hormones and surgical procedures for their gender affirmation and 47% report having negative experiences when receiving health services due to their gender identity [11].

In Asia, between 2012 and 2018, HIV prevalence among transgender women ranged from 0.9% to 34% [12]. Providing transgender-led, integrated hormone and sexual health services has been a growing priority in the region over the past four years as a mechanism to enhance access to HIV-related services. This effort has been led by the Tangerine Community Health Center in Bangkok, Thailand, where its services have significantly increased repeat HIV testing and PrEP uptake [13,14]. The model has recently been expanded to Hanoi and Ho Chi Minh City in Vietnam, and Manila in the Philippines [15].

Notwithstanding the expansion of this peer-led intervention, only 5.8% of an estimated 9209 transgender women at high-risk of HIV acquisition in Thailand have accessed PrEP since its adoption in 2015, [16] underscoring the need for more implementation research to scale-up proven interventions, as well as research to identify innovative approaches to service delivery which are more friendly/tailored to transgender women.

Equally important to these advances in access to transgender-competent health care is the need to strengthen legal protections and advocacy around human rights. On multiple levels, it is clear that transgender-led research produce the most meaningful data. This research is being enhanced through increasingly collaborative trans-cis effort in Asia as shown in examples above. Participatory trans-cis research is crucial, and recent comments advocating the exclusion or minimization of cis-gender researchers are not constructive [17], if we are going to accelerate a transgender research agenda.

Millions of women worldwide over the age of 50 are living with HIV – but their successes, challenges and future prospects are rarely heard. The majority of these women reside in sub-Saharan Africa, but there are hundreds of thousands living in high-, low- or middle-income regions around the world. Congruent with expanded antiretroviral treatment access, their numbers will continue to increase over the next decade [18]. We have been complacent about understanding the biomedical changes and societal barriers for these women; and research investment is lacking [19]. Women, like men, are at increased risk for cardiac disease, malignancies and bone disease as they age [20]; some conditions such as bone disease are amplified among peri- or post-menopausal women. Knowledge of the consequences of the extraordinary weight gains associated with dolutegravir are as yet unknown, but differentially affect women [21]. There are enormous unmet behavioural health needs for women throughout life, particularly associated with ageing, where depression and loneliness, coupled with cognitive decline, can lead to a downhill spiral and premature death [22].

The health and wellbeing of women ageing with HIV is also particularly affected by cultural norms that violate their fundamental human rights. Lack of property ownership and gender-based violence can precipitate or exacerbate poverty, food security and access to care [23]. Women in polygamous

marriages may lose stature and resources as they age. Around the world, women over 50 who do not have HIV are often not considered “at risk” to acquire HIV, are tested less frequently than men, and are less likely to seek PrEP [24,25]. Yet, 22,000 women over 50 newly acquired HIV in southern and eastern Africa in 2018 alone [26].

Women across their lifespan fulfil many and multiple roles in society including being caretakers and educators in formal and informal settings, which largely goes unrecognized and is unrewarded. Moving towards the UN 2030 goal of ending AIDS as a public health threat calls for new and concerted efforts to:

- 1 ensure that innovation in prevention and treatment efforts include women, especially AGYW and pregnant women, from the outset to minimize data gaps and delays in access to effective interventions
- 2 prevent HIV in AGYW has to address the underlying gender-power differences at the root cause of their vulnerability and therefore has to include testing and treatment targeting men and older women and gender sensitive interventions for adolescent boys including VMMC and comprehensive sexuality education.
- 3 strengthen transgender-led effort to attain legal and human rights, as well as transgender-competent care, including those related to HIV treatment and prevention
- 4 increase investments in research and care for all women of all ages to prevent or treat HIV
- 5 continued innovation for less user-dependent women-initiated HIV prevention technologies including vaccines are urgently needed to expand the array of safe and effective prevention options for women.

By ensuring that no women – from birth to death – experience barriers to access to the full range of HIV prevention and care services or violation of their basic human rights, all of society benefits.

AUTHORS' AFFILIATIONS

¹Centre for the AIDS Programme of Research in South Africa, Nelson Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; ²Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; ³Department of Medicine, University of California, San Francisco, CA, USA; ⁴PREVENTION, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

COMPETING INTERESTS

QAK and NP declared no competing interest. DH receives non-financial support from Gilead Sciences.

AUTHORS' CONTRIBUTIONS

DH, NP and QAK contributed equally to this viewpoint. QAK, DH and NP wrote the adolescent and young cisgender women, cisgender women who are ageing, and transgender women respectively. All authors reviewed critically and approved the final manuscript.

REFERENCES

1. UNAIDS. Miles to go: closing gaps, breaking barriers, righting injustices. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2018.
2. de Oliveira T, Kharsany AB, Graf T, Cawood C, Khanyile D, Grobler A, et al. Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. *Lancet HIV*. 2017;4(1):e41–50.

3. McKinnon LR, Liebenberg LJ, Yende-Zuma N, Archary D, Ngcapu S, Sivro A, et al. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. *Nat Med*. 2018;24(4):491–6.
4. Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, et al. Genital inflammation and the risk of HIV acquisition in women. *Clin Infect Dis*. 2015;61(2):260–9.
5. Klatt NR, Cheu R, Birse K, Zevin AS, Perner M, Noel-Romas L, et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. *Science*. 2017;356(6341):938–45.
6. Kalichman SC, Simbayi LC, Kagee A, Toefy Y, Jooste S, Cain D, et al. Associations of poverty, substance use, and HIV transmission risk behaviors in three South African communities. *Soc Sci Med*. 2006;62(7):1641–9.
7. Abdool Karim Q, Baxter C. The dual burden of gender-based violence and HIV in adolescent girls and young women in South Africa. *S Afr Med J*. 2016;106(12):1151–3.
8. Zaba B, Calvert C, Marston M, Isingo R, Nakiyingi-Miiri J, Lutalo T, et al. Effect of HIV infection on pregnancy-related mortality in sub-Saharan Africa: secondary analyses of pooled community-based data from the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA). *Lancet*. 2013;381(9879):1763–71.
9. Abdool Karim Q, Baxter C, Bix D. Prevention of HIV in adolescent girls and young women: key to an AIDS-free generation. *J Acquir Immune Defic Syndr*. 2017;75 Suppl 1:S17–26.
10. Winter S, Diamond M, Green J, Karasic D, Reed T, Whittle S, et al. Transgender people: health at the margins of society. *Lancet*. 2016;388(10042):390–400.
11. Transgender Europe. *Transrespect versus Transphobia: The social experiences of trans and gender-diverse people in Colombia, India, the Philippines, Serbia, Thailand, Tonga, Turkey and Venezuela* [cited 2020 Feb 6]. Available from: <https://transrespect.org/wp-content/uploads/2015/08/TvT-PS-Vol9-2015.pdf>
12. HIV and AIDS Datahub for Asia Pacific. *Review in slides: transgender people (male-to-female)* [cited 2020 Feb 6]. Available from: https://www.aidsdatahub.org/sites/default/files/TG_Slides_December_2019
13. Yang F, Janamnuaysook R, Boyd MA, Phanuphak N, Tucker JD. Key populations and power: people-centred social innovation in Asian HIV services. *Lancet HIV*. 2020;7(1):e69–74.
14. Janamnuaysook R, Samitpol K, Ketwongsa P, Chancham A, Kongkapan J, Mingkwanrungruang P, et al. Integrated gender affirmative hormone treatment services improve access to and retention in HIV testing, syphilis testing and pre-exposure prophylaxis (PrEP) service uptake among transgender women in Thailand. The 22nd International AIDS Conference, 23–27 July 2018, Amsterdam, Netherlands, Abstract Number THAC0204.
15. PREVENTION. Thai Red Cross AIDS Research Centre. *Advancing health services for transgender people in Asia-Pacific Region* [cited 2020 Feb 6]. Available from: <https://www.prevention-trcarc.org/en/news/Advancing-health-service-for-transgender-people-in-Asia-Pacific-Region>
16. Ramutarsing R. PrEP in Thailand. The 22nd Bangkok International Symposium on HIV Medicine, 15 January 2020, Bangkok, Thailand. [cited 2020 Feb 6]. Available from: <https://drive.google.com/drive/folders/1QxkpLaq23Fr3abkv6pymbdC-jK0zgm4b>
17. Scheim AI, Appenroth MN, Beckham SW, Goldstein Z, Grinspan MC, Keatley JG, et al. Transgender HIV research: nothing about us without us. *Lancet HIV*. 2019;6(9):e566–7.
18. Autenrieth CS, Beck EJ, Stelzle D, Mallouris C, Mahy M, Ghys P. Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000–2020. *PLoS one*. 2018;13:e0207005.
19. Adam GP, Di M, Cu-Uvin S, Halladay C, Smith BT, Iyer S, et al. Strategies for improving the lives of US women aged 40 and above living with HIV/AIDS: an evidence map. *Syst Rev*. 2018;7(1):25.
20. Siedner MJ. Aging, health, and quality of life for older people living with HIV in Sub-Saharan Africa: a review and proposed conceptual framework. *J Aging Health*. 2019;31(1):109–38.
21. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. *N Engl J Med*. 2019;381(9):803–15.
22. Meffert SM, Neylan TC, McCulloch CE, Maganga L, Adamu Y, Kiweewa F, et al. East African HIV care: depression and HIV outcomes. *Glob Ment Health*. 2019;6:e9.
23. Anderson S. Legal origins and female HIV. *Am Econ Rev*. 2018;108(5):1407–89.
24. Schatz E, Seeley J, Negin J, Weiss HA, Tumwekwase G, Kabunga E, et al. "For us here, we remind ourselves": strategies and barriers to ART access and adherence among older Ugandans. *BMC Public Health*. 2019;19(1):131.
25. Schatz E, Knight L. "I was referred from the other side": Gender and HIV testing among older South Africans living with HIV. *PLoS One*. 2018;13:e0196158.
26. Global HIV & AIDS Statistics – 2019 fact sheet [cited 2020 Feb 6]. Available from: <https://www.unaids.org/en/resources/fact-sheet>